

## Supplementary Material S1. Searching Strategy

- #1 "Esophagitis, Peptic"[Mesh]
- #2 (Esophagitides, Peptic[Title/Abstract]) OR (Peptic Esophagitides[Title/Abstract]) OR (Peptic Esophagitis[Title/Abstract]) OR (Esophagitis, Reflux[Title/Abstract]) OR (Esophagitides, Reflux[Title/Abstract]) OR (Reflux Esophagitides[Title/Abstract]) OR (Reflux Esophagitis[Title/Abstract]) OR (Erosive esophagitis[Title/Abstract])
- #3 #1 OR #2
- #4 "Proton Pump Inhibitors"[Mesh]
- #5 Inhibitors, Proton Pump[Title/Abstract] OR (Proton Pump Inhibitor[Title/Abstract]) OR (Inhibitor, Proton Pump[Title/Abstract]) OR (Pump Inhibitor, Proton[Title/Abstract])
- #6 "Omeprazole"[Mesh]
- #7 (Prilosec[Title/Abstract]) OR (H 168-68[Title/Abstract]) OR (H 168 68[Title/Abstract]) OR (H 16868[Title/Abstract])
- #8 "Rabeprazole"[Mesh]
- #9 (2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole[Title/Abstract]) OR (Dexrabeprazole[Title/Abstract]) OR (E 3810[Title/Abstract]) OR (E3810[Title/Abstract]) OR (Pariet[Title/Abstract]) OR (Aciphex[Title/Abstract]) OR (LY-307640[Title/Abstract]) OR (LY 307640[Title/Abstract]) OR (LY307640[Title/Abstract])
- #10 "Lansoprazole"[Mesh]
- #11 (Lansoprazol[Title/Abstract]) OR (2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole[Title/Abstract]) OR (Lansoprazoles[Title/Abstract]) OR (Ogastro[Title/Abstract]) OR (AG 1749[Title/Abstract]) OR (AG-1749[Title/Abstract]) OR (AG1749[Title/Abstract]) OR (Agopton[Title/Abstract]) OR (Bamalite[Title/Abstract]) OR (Lansol[Title/Abstract]) OR (Lanzor[Title/Abstract]) OR (Monolimum[Title/Abstract]) OR (Opiren[Title/Abstract]) OR (Prevacid[Title/Abstract]) OR (Pro Ulco[Title/Abstract]) OR (Promeco[Title/Abstract]) OR (Takepron[Title/Abstract]) OR (Ulpax[Title/Abstract]) OR (Zoton[Title/Abstract]) OR (Ogast[Title/Abstract]) OR (Prezal[Title/Abstract])
- #12 "Esomeprazole"[Mesh]
- #13 (Esomeprazole Sodium[Title/Abstract]) OR (Esomeprazole Strontium[Title/Abstract]) OR (Strontium, Esomeprazole[Title/Abstract]) OR (Esomeprazole Magnesium[Title/Abstract]) OR (Esomeprazole Potassium[Title/Abstract]) OR (Esomeprazole Strontium Anhydrous[Title/Abstract]) OR (Nexium[Title/Abstract])
- #14 "Pantoprazole"[Mesh]
- #15 (SKF-96022[Title/Abstract]) OR (SKF 96022[Title/Abstract]) OR (SKF96022[Title/Abstract]) OR (BY 1023[Title/Abstract]) OR (BY-1023[Title/Abstract]) OR (BY1023[Title/Abstract]) OR (Protonix[Title/Abstract])
- #16 "ilaprazole" [Supplementary Concept]
- #17 (IY 81149[Title/Abstract]) OR (IY81149[Title/Abstract]) OR (IY-81149[Title/Abstract])
- #18 ("1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine" [Supplementary Concept])
- #19 (Vonoprazan[Title/Abstract]) OR (TAK 438[Title/Abstract]) OR (TAK438[Title/Abstract]) OR (TAK-438[Title/Abstract])
- #20 "dexlansoprazole"[MeSH Terms]
- #21 (Delanzo[Title/Abstract]) OR (Dexilant[Title/Abstract]) OR (TAK 390MR[Title/Abstract]) OR

(Kapidex[Title/Abstract])

#22 (potassium competitive acid blocker[Title/Abstract]) OR (PCAB[Title/Abstract]) OR (acid pump antagonist[Title/Abstract])

#23 (Tegoprazan[Title/Abstract]) OR (LXI-15028[Title/Abstract]) OR (LXI 15028[Title/Abstract]) OR (LXI15028[Title/Abstract])

#24 (keverprazan[Title/Abstract]) or (H008[Title/Abstract])


#25 (YH1885L[Title/Abstract]) OR (Revaprazan[Title/Abstract])

#26 #4~#25 OR


#27 ("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "drug therapy"[MeSH Subheading] OR "randomly"[Title/Abstract] OR "trial"[Title/Abstract] OR "groups"[Title/Abstract]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])

#28 #3 AND #26 AND #27


(A)




(B)



**Figure S1 Risk of bias for the included randomized controlled trials: (A) proportion of studies with each judgment and (B) all judgments in a cross-tabulation of studies by entry. The numerical values indicate Study IDs, which are consistent with those presented in Table 1.**



**Figure S2. Funnel plots for 4-week healing rate. (A) Main analysis. (B) Sensitivity analysis. (C) Subgroup analysis on patients without severe baseline grade. (D) Subgroup analysis on patients with severe baseline grade.**



**Figure S3. Funnel plots for 8-week healing rate. (A) Main analysis. (B) Sensitivity analysis. (C) Subgroup analysis on patients without severe baseline grade. (D) Subgroup analysis on patients with severe baseline grade.**

**Table S1 Odds ratios of relative 4-week healing rate for each treatment in the main analysis**

Vpz40	0.55 (0.17,1.76)	0.35 (0.10,1.26)	<b>0.24</b> <b>(0.06,0.99)</b>	0.04 (0.01,0.13)	0.41 (0.13,1.36)	0.45 (0.12,1.72)	0.36 (0.11,1.17)	0.37 (0.09,1.44)	0.40 (0.13,1.29)	0.43 (0.11,1.69)	0.94 (0.24,3.75)	0.54 (0.17,1.76)
1.83 (0.57,5.87)	Vpz20	0.65 (0.33,1.28)	0.43 (0.17,1.12)	0.07 (0.04,0.13)	0.75 (0.45,1.28)	0.82 (0.36,1.85)	0.66 (0.39,1.09)	0.67 (0.29,1.56)	0.74 (0.47,1.16)	0.78 (0.33,1.85)	1.72 (0.71,4.13)	0.99 (0.60,1.63)
2.82 (0.79,10.05)	1.55 (0.78,3.06)	Rab20	0.67 (0.31,1.47)	0.11 (0.06,0.20)	1.17 (0.69,1.95)	1.26 (0.57,2.78)	1.01 (0.64,1.60)	1.04 (0.44,2.46)	1.14 (0.68,1.90)	1.21 (0.49,2.94)	2.65 (1.11,6.34)	1.53 (0.93,2.49)
<b>4.21</b> <b>(1.01,17.61)</b>	2.30 (0.89,5.95)	1.49 (0.68,3.27)	Rab10	0.17 (0.07,0.40)	1.74 (0.75,4.02)	1.88 (0.67,5.27)	1.51 (0.68,3.37)	1.54 (0.52,4.58)	1.70 (0.74,3.91)	1.80 (0.59,5.46)	3.96 (1.33,11.79)	2.27 (1.00,5.18)
25.11 (7.45,84.63)	13.74 (7.74,24.41)	8.89 (4.99,15.84)	5.97 (2.48,14.35)	Placebo	10.36 (7.06,15.19)	11.22 (5.49,22.92)	9.01 (6.30,12.87)	9.21 (4.51,18.82)	10.13 (7.12,14.41)	10.72 (4.76,24.17)	23.60 (10.54,52.85)	13.56 (9.39,19.57)
2.42 (0.74,7.99)	1.33 (0.78,2.25)	0.86 (0.51,1.44)	0.58 (0.25,1.33)	0.10 (0.07,0.14)	Pan40	1.08 (0.54,2.15)	0.87 (0.68,1.11)	0.89 (0.42,1.88)	0.98 (0.75,1.28)	1.04 (0.47,2.26)	2.28 (1.08,4.81)	1.31 (1.06,1.61)
2.24 (0.58,8.61)	1.22 (0.54,2.77)	0.79 (0.36,1.74)	0.53 (0.19,1.49)	0.09 (0.04,0.18)	0.92 (0.46,1.84)	Ome40	0.80 (0.42,1.53)	0.82 (0.31,2.16)	0.90 (0.46,1.78)	0.96 (0.35,2.60)	2.10 (0.79,5.61)	1.21 (0.62,2.36)
2.79 (0.85,9.12)	1.53 (0.92,2.54)	0.99 (0.63,1.55)	0.66 (0.30,1.48)	0.11 (0.08,0.16)	1.15 (0.90,1.47)	1.25 (0.65,2.38)	Ome20	1.02 (0.49,2.13)	1.12 (0.89,1.42)	1.19 (0.55,2.57)	2.62 (1.25,5.50)	1.51 (1.25,1.82)
2.73 (0.70,10.67)	1.49 (0.64,3.48)	0.96 (0.41,2.29)	0.65 (0.22,1.92)	0.11 (0.05,0.22)	1.12 (0.53,2.37)	1.22 (0.46,3.20)	0.98 (0.47,2.04)	Lan60	1.10 (0.54,2.25)	1.16 (0.42,3.24)	2.56 (0.92,7.15)	1.47 (0.71,3.07)
2.48 (0.77,7.93)	1.36 (0.86,2.14)	0.88 (0.53,1.46)	0.59 (0.26,1.36)	0.10 (0.07,0.14)	1.02 (0.78,1.34)	1.11 (0.56,2.19)	0.89 (0.71,1.12)	0.91 (0.45,1.86)	Lan30	1.06 (0.51,2.20)	2.33 (1.10,4.93)	1.34 (1.07,1.67)
2.34 (0.59,9.26)	1.28 (0.54,3.03)	0.83 (0.34,2.02)	0.56 (0.18,1.69)	0.09 (0.04,0.21)	0.97 (0.44,2.11)	1.05 (0.39,2.84)	0.84 (0.39,1.81)	0.86 (0.31,2.39)	0.94 (0.45,1.97)	Kev20	2.20 (0.77,6.28)	1.26 (0.59,2.72)
1.06 (0.27,4.25)	0.58 (0.24,1.40)	<b>0.38</b> <b>(0.16,0.90)</b>	<b>0.25</b> <b>(0.08,0.75)</b>	0.04 (0.02,0.09)	<b>0.44</b> <b>(0.21,0.93)</b>	0.48 (0.18,1.27)	<b>0.38</b> <b>(0.18,0.80)</b>	0.39 (0.14,1.09)	<b>0.43</b> <b>(0.20,0.91)</b>	0.45 (0.16,1.30)	Ila10	0.57 (0.28,1.18)
1.85 (0.57,6.05)	1.01 (0.61,1.68)	0.66 (0.40,1.07)	<b>0.44</b> <b>(0.19,1.00)</b>	0.07 (0.05,0.11)	<b>0.76</b> <b>(0.62,0.94)</b>	0.83 (0.42,1.62)	<b>0.66</b> <b>(0.55,0.80)</b>	0.68 (0.33,1.42)	<b>0.75</b> <b>(0.60,0.93)</b>	0.79 (0.37,1.70)	1.74 (0.85,3.57)	Eso40

**Table S2 Odds ratios of relative 4-week healing rate for each treatment in the sensitivity analysis**

Vpz40	0.55 (0.17,1.76)	0.54 (0.12,2.42)	0.68 (0.15,3.12)	0.35 (0.10,1.27)	0.24 (0.06,1.00)	0.04 (0.01,0.13)	0.41 (0.12,1.37)	0.45 (0.12,1.73)	0.36 (0.11,1.18)	0.37 (0.09,1.44)	0.40 (0.13,1.29)	0.43 (0.11,1.70)	0.62 (0.17,2.18)	0.65 (0.14,2.99)	0.54 (0.16,1.77)
1.83 (0.57,5.88)	Vpz20	0.99 (0.35,2.81)	1.25 (0.43,3.66)	0.65 (0.33,1.29)	0.43 (0.17,1.13)	0.07 (0.04,0.13)	0.75 (0.44,1.28)	0.82 (0.36,1.86)	0.66 (0.39,1.10)	0.67 (0.29,1.57)	0.74 (0.47,1.16)	0.78 (0.33,1.86)	1.13 (0.58,2.19)	1.20 (0.41,3.50)	0.99 (0.59,1.64)
1.85 (0.41,8.29)	1.01 (0.36,2.89)	Teg50	1.27 (0.49,3.27)	0.66 (0.23,1.86)	0.44 (0.13,1.51)	0.07 (0.03,0.20)	0.76 (0.30,1.96)	0.83 (0.27,2.58)	0.67 (0.26,1.69)	0.68 (0.21,2.20)	0.75 (0.29,1.92)	0.79 (0.24,2.61)	1.14 (0.42,3.13)	1.21 (0.33,4.52)	1.00 (0.40,2.50)
1.46 (0.32,6.68)	0.80 (0.27,2.35)	0.79 (0.31,2.04)	Teg100	0.52 (0.18,1.51)	0.35 (0.10,1.22)	0.06 (0.02,0.16)	0.60 (0.23,1.59)	0.65 (0.20,2.09)	0.52 (0.20,1.38)	0.54 (0.16,1.78)	0.59 (0.22,1.56)	0.62 (0.18,2.12)	0.90 (0.32,2.55)	0.96 (0.25,3.65)	0.79 (0.31,2.04)
2.82 (0.79,10.09)	1.55 (0.78,3.07)	1.52 (0.54,4.31)	1.93 (0.66,5.63)	Rab20	0.67 (0.30,1.48)	0.11 (0.06,0.20)	1.16 (0.69,1.96)	1.26 (0.57,2.80)	1.01 (0.64,1.60)	1.04 (0.43,2.47)	1.14 (0.68,1.90)	1.21 (0.49,2.96)	1.74 (0.91,3.34)	1.85 (0.64,5.38)	1.52 (0.93,2.50)
<b>4.21</b> <b>(1.00,17.68)</b>	2.30 (0.89,5.99)	2.27 (0.66,7.80)	2.88 (0.82,10.13)	1.49 (0.68,3.29)	Rab10	0.17 (0.07,0.41)	1.74 (0.75,4.04)	1.88 (0.67,5.30)	1.51 (0.67,3.38)	1.54 (0.52,4.60)	1.70 (0.73,3.93)	1.80 (0.59,5.49)	2.59 (1.02,6.58)	2.75 (0.78,9.68)	2.27 (0.99,5.20)
25.10 (7.42,84.92)	13.75 (7.70,24.54)	13.55 (5.05,36.37)	17.17 (6.20,47.51)	8.89 (4.97,15.92)	5.97 (2.47,14.43)	Placebo	10.36 (7.04,15.25)	11.23 (5.47,23.07)	9.01 (6.28,12.93)	9.21 (4.49,18.89)	10.12 (7.09,14.45)	10.72 (4.73,24.30)	15.48 (8.80,27.23)	16.44 (5.95,45.41)	13.55 (9.35,19.65)
2.42 (0.73,8.02)	1.33 (0.78,2.26)	1.31 (0.51,3.35)	1.66 (0.63,4.38)	0.86 (0.51,1.45)	0.58 (0.25,1.34)	0.10 (0.07,0.14)	Pan40	1.08 (0.54,2.17)	0.87 (0.68,1.12)	0.89 (0.42,1.88)	0.98 (0.74,1.28)	1.03 (0.47,2.27)	1.49 (0.93,2.40)	1.59 (0.60,4.18)	1.31 (1.06,1.62)

2.24 (0.58,8.64)	1.22 (0.54,2.79)	1.21 (0.39,3.76)	1.53 (0.48,4.90)	0.79 (0.36,1.75)	0.53 (0.19,1.50)	0.09 (0.04,0.18)	0.92 (0.46,1.84)	Ome40	0.80 (0.42,1.54)	0.82 (0.31,2.17)	0.90 (0.45,1.79)	0.95 (0.35,2.61)	1.38 (0.62,3.06)	1.46 (0.46,4.68)	1.21 (0.61,2.37)
2.79 (0.85,9.15)	1.53 (0.91,2.55)	1.50 (0.59,3.83)	1.90 (0.72,5.01)	0.99 (0.62,1.56)	0.66 (0.30,1.48)	0.11 (0.08,0.16)	1.15 (0.89,1.48)	1.25 (0.65,2.39)	Ome20	1.02 (0.49,2.14)	1.12 (0.89,1.42)	1.19 (0.55,2.58)	1.72 (1.08,2.74)	1.82 (0.69,4.79)	1.50 (1.24,1.82)
2.73 (0.69,10.72 )	1.49 (0.64,3.50)	1.47 (0.45,4.77)	1.86 (0.56,6.20)	0.97 (0.41,2.30)	0.65 (0.22,1.93)	0.11 (0.05,0.22)	1.12 (0.53,2.38)	1.22 (0.46,3.23)	0.98 (0.47,2.05)	Lan60	1.10 (0.54,2.25)	1.16 (0.42,3.26)	1.68 (0.72,3.95)	1.78 (0.54,5.93)	1.47 (0.70,3.08)
2.48 (0.77,7.96)	1.36 (0.86,2.15)	1.34 (0.52,3.43)	1.70 (0.64,4.49)	0.88 (0.53,1.47)	0.59 (0.25,1.36)	0.10 (0.07,0.14)	1.02 (0.78,1.34)	1.11 (0.56,2.20)	0.89 (0.70,1.13)	0.91 (0.44,1.87)	Lan30	1.06 (0.51,2.21)	1.53 (0.94,2.48)	1.62 (0.61,4.29)	1.34 (1.07,1.68)
2.34 (0.59,9.30)	1.28 (0.54,3.06)	1.26 (0.38,4.18)	1.60 (0.47,5.43)	0.83 (0.34,2.04)	0.56 (0.18,1.70)	0.09 (0.04,0.21)	0.97 (0.44,2.12)	1.05 (0.38,2.87)	0.84 (0.39,1.82)	0.86 (0.31,2.41)	0.94 (0.45,1.97)	Kev20	1.44 (0.60,3.49)	1.53 (0.45,5.20)	1.26 (0.59,2.73)
1.62 (0.46,5.72)	0.89 (0.46,1.72)	0.88 (0.32,2.40)	1.11 (0.39,3.14)	0.57 (0.30,1.10)	<b>0.39</b> <b>(0.15,0.98)</b>	0.06 (0.04,0.11)	0.67 (0.42,1.08)	0.73 (0.33,1.61)	<b>0.58</b> <b>(0.37,0.93)</b>	0.59 (0.25,1.40)	0.65 (0.40,1.06)	0.69 (0.29,1.67)	Ila10	1.06 (0.38,3.00)	0.88 (0.57,1.34)
1.53 (0.33,6.97)	0.84 (0.29,2.45)	0.82 (0.22,3.07)	1.04 (0.27,3.98)	0.54 (0.19,1.57)	0.36 (0.10,1.28)	0.06 (0.02,0.17)	0.63 (0.24,1.66)	0.68 (0.21,2.18)	0.55 (0.21,1.44)	0.56 (0.17,1.86)	0.62 (0.23,1.63)	0.65 (0.19,2.21)	0.94 (0.33,2.66)	Fex40	0.82 (0.32,2.12)
1.85 (0.57,6.07)	1.01 (0.61,1.69)	1.00 (0.40,2.50)	1.27 (0.49,3.27)	0.66 (0.40,1.08)	0.44 (0.19,1.01)	0.07 (0.05,0.11)	<b>0.76</b> <b>(0.62,0.95)</b>	0.83 (0.42,1.63)	<b>0.67</b> <b>(0.55,0.81)</b>	0.68 (0.32,1.42)	<b>0.75</b> <b>(0.60,0.93)</b>	0.79 (0.37,1.71)	1.14 (0.75,1.75)	1.21 (0.47,3.12)	Eso40



**Table S3 Odds ratios of relative 4-week healing rate for each treatment in the subgroup analysis on patients without severe baseline grade**

Vpz40	0.32 (0.07,1.49)	0.03 (0.01,0.16)	0.24 (0.04,1.38)	0.29 (0.06,1.55)	0.42 (0.08,2.09)	0.50 (0.07,3.46)	0.27 (0.05,1.49)
3.15 (0.67,14.76)	Vpz20	0.09 (0.04,0.21)	0.76 (0.30,1.94)	0.92 (0.42,2.02)	1.31 (0.67,2.55)	1.57 (0.45,5.54)	0.85 (0.35,2.04)
35.16 (6.44,192.05)	11.18 (4.76,26.22)	Placebo	8.55 (4.33,16.88)	10.31 (6.33,16.81)	14.65 (8.84,24.28)	17.59 (5.40,57.35)	9.46 (5.22,17.11)
4.11 (0.72,23.39)	1.31 (0.52,3.32)	0.12 (0.06,0.23)	Pan40	1.21 (0.75,1.93)	1.71 (0.94,3.14)	2.06 (0.60,7.03)	1.11 (0.67,1.83)
3.41 (0.65,18.01)	1.08 (0.49,2.38)	0.10 (0.06,0.16)	0.83 (0.52,1.33)	Ome20	1.42 (0.98,2.05)	1.71 (0.55,5.28)	0.92 (0.66,1.28)
2.40 (0.48,12.03)	0.76 (0.39,1.48)	0.07 (0.04,0.11)	0.58 (0.32,1.07)	0.70 (0.49,1.02)	Lan30	1.20 (0.41,3.49)	0.65 (0.39,1.07)
2.00 (0.29,13.83)	0.64 (0.18,2.24)	0.06 (0.02,0.19)	0.49 (0.14,1.66)	0.59 (0.19,1.81)	0.83 (0.29,2.42)	Kev20	0.54 (0.16,1.76)
3.72 (0.67,20.58)	1.18 (0.49,2.85)	0.11 (0.06,0.19)	0.90 (0.55,1.50)	1.09 (0.78,1.52)	1.55 (0.93,2.58)	1.86 (0.57,6.08)	Eso40

**Table S4 Odds ratios of relative 4-week healing rate for each treatment in the subgroup analysis on patients with severe baseline grade**

Vpz40	0.79 (0.16,3.91)	0.03 (0.01,0.15)	0.41 (0.07,2.38)	0.35 (0.08,1.63)	0.31 (0.06,1.63)	0.38 (0.08,1.70)	0.49 (0.07,3.40)	0.56 (0.12,2.57)
1.27 (0.26,6.28)	Vpz20	0.04 (0.02,0.09)	0.52 (0.18,1.56)	0.44 (0.22,0.89)	0.39 (0.15,1.01)	0.48 (0.26,0.89)	0.62 (0.16,2.45)	0.71 (0.37,1.37)
33.76 (6.78,168.03)	26.65 (11.52,61.64)	Placebo	13.93 (4.88,39.77)	11.85 (6.43,21.83)	10.35 (4.94,21.69)	12.81 (7.23,22.70)	16.47 (4.22,64.22)	19.00 (10.39,34.76)
2.42 (0.42,13.96)	1.91 (0.64,5.70)	0.07 (0.03,0.20)	Pan40	0.85 (0.35,2.04)	0.74 (0.23,2.36)	0.92 (0.37,2.27)	1.18 (0.26,5.46)	1.36 (0.56,3.33)
2.85 (0.61,13.20)	<b>2.25</b> <b>(1.13,4.49)</b>	0.08 (0.05,0.16)	1.18 (0.49,2.82)	Ome20	0.87 (0.40,1.91)	1.08 (0.78,1.49)	1.39 (0.39,4.98)	1.60 (1.17,2.20)
3.26 (0.61,17.34)	2.58 (0.99,6.71)	0.10 (0.05,0.20)	1.35 (0.42,4.28)	1.15 (0.52,2.51)	Lan60	1.24 (0.59,2.58)	1.59 (0.38,6.70)	1.84 (0.85,3.95)
2.64 (0.59,11.80)	<b>2.08</b> <b>(1.13,3.84)</b>	0.08 (0.04,0.14)	1.09 (0.44,2.68)	0.93 (0.67,1.28)	0.81 (0.39,1.68)	Lan30	1.29 (0.37,4.42)	1.48 (1.18,1.87)
2.05 (0.29,14.30)	1.62 (0.41,6.42)	0.06 (0.02,0.24)	0.85 (0.18,3.91)	0.72 (0.20,2.58)	0.63 (0.15,2.64)	0.78 (0.23,2.67)	Kev20	1.15 (0.33,4.05)
1.78 (0.39,8.10)	1.40 (0.73,2.70)	0.05 (0.03,0.10)	0.73 (0.30,1.79)	<b>0.62</b> <b>(0.45,0.86)</b>	0.54 (0.25,1.17)	<b>0.67</b> <b>(0.54,0.85)</b>	0.87 (0.25,3.04)	Eso40

**Table S5 Odds ratios of relative 8-week healing rate for each treatment in the main analysis**

Vpz40	1.03 (0.28,3.77)	0.40 (0.09,1.81)	0.36 (0.06,1.99)	0.04 (0.01,0.16)	0.67 (0.17,2.58)	0.51 (0.11,2.42)	0.49 (0.13,1.85)	0.45 (0.09,2.27)	0.55 (0.15,1.99)	1.40 (0.24,8.29)	1.21 (0.23,6.35)	0.85 (0.22,3.21)
0.97 (0.27,3.54)	Vpz20	0.38 (0.15,0.99)	0.35 (0.10,1.19)	0.04 (0.02,0.08)	0.65 (0.34,1.22)	0.50 (0.18,1.34)	0.47 (0.26,0.86)	0.43 (0.14,1.31)	0.53 (0.33,0.87)	1.36 (0.36,5.08)	1.17 (0.37,3.72)	0.82 (0.45,1.49)
2.52 (0.55,11.53)	<b>2.60</b> <b>(1.01,6.68)</b>	Rab20	0.90 (0.32,2.57)	0.10 (0.04,0.25)	1.69 (0.74,3.84)	1.30 (0.44,3.86)	1.23 (0.60,2.55)	1.13 (0.32,3.92)	1.38 (0.62,3.10)	3.54 (0.82,15.31)	3.04 (0.86,10.80)	2.13 (0.97,4.71)
2.80 (0.50,15.60)	2.89 (0.84,9.96)	1.11 (0.39,3.16)	Rab10	0.12 (0.04,0.38)	1.87 (0.59,5.91)	1.44 (0.37,5.57)	1.37 (0.46,4.04)	1.25 (0.28,5.51)	1.54 (0.49,4.79)	3.93 (0.74,20.86)	3.37 (0.75,15.12)	2.37 (0.77,7.31)
24.03 (6.12,94.38)	24.80 (12.66,48.58)	9.53 (4.03,22.50)	8.59 (2.65,27.83)	Placebo	16.07 (9.77,26.44)	12.35 (5.23,29.14)	11.74 (7.43,18.55)	10.73 (4.09,28.16)	13.19 (8.33,20.89)	33.73 (9.13,124.57)	28.97 (9.58,87.62)	20.34 (12.42,33.32)
1.50 (0.39,5.76)	1.54 (0.82,2.90)	0.59 (0.26,1.35)	0.53 (0.17,1.69)	0.06 (0.04,0.10)	Pan40	0.77 (0.32,1.85)	0.73 (0.50,1.07)	0.67 (0.24,1.87)	0.82 (0.55,1.22)	2.10 (0.58,7.60)	1.80 (0.63,5.15)	1.27 (0.89,1.79)
1.95 (0.41,9.17)	2.01 (0.74,5.42)	0.77 (0.26,2.30)	0.70 (0.18,2.69)	0.08 (0.03,0.19)	1.30 (0.54,3.14)	Ome40	0.95 (0.42,2.14)	0.87 (0.25,3.07)	1.07 (0.45,2.53)	2.73 (0.61,12.20)	2.35 (0.63,8.71)	1.65 (0.70,3.89)
2.05 (0.54,7.77)	<b>2.11</b> <b>(1.16,3.85)</b>	0.81 (0.39,1.68)	0.73 (0.25,2.16)	0.09 (0.05,0.13)	1.37 (0.93,2.01)	1.05 (0.47,2.37)	Ome20	0.91 (0.33,2.52)	1.12 (0.80,1.59)	2.87 (0.81,10.24)	2.47 (0.87,6.97)	1.73 (1.27,2.36)
2.24 (0.44,11.38)	2.31 (0.76,6.99)	0.89 (0.26,3.09)	0.80 (0.18,3.53)	0.09 (0.04,0.24)	1.50 (0.53,4.21)	1.15 (0.33,4.06)	1.09 (0.40,3.01)	Lan60	1.23 (0.46,3.31)	3.14 (0.65,15.17)	2.70 (0.65,11.23)	1.90 (0.68,5.28)
1.82 (0.50,6.61)	<b>1.88</b> <b>(1.15,3.07)</b>	0.72 (0.32,1.62)	0.65 (0.21,2.03)	0.08 (0.05,0.12)	1.22 (0.82,1.82)	0.94 (0.40,2.22)	0.89 (0.63,1.26)	0.81 (0.30,2.19)	Lan30	2.56 (0.75,8.69)	2.20 (0.77,6.28)	1.54 (1.09,2.18)
0.71 (0.12,4.21)	0.74 (0.20,2.75)	0.28 (0.07,1.22)	0.25 (0.05,1.35)	0.03 (0.01,0.11)	0.48 (0.13,1.73)	0.37 (0.08,1.63)	0.35 (0.10,1.24)	0.32 (0.07,1.54)	0.39 (0.12,1.33)	Kev20	0.86 (0.17,4.30)	0.60 (0.17,2.15)
0.83 (0.16,4.37)	0.86 (0.27,2.73)	0.33 (0.09,1.17)	0.30 (0.07,1.33)	0.03 (0.01,0.10)	0.55 (0.19,1.59)	0.43 (0.11,1.58)	0.41 (0.14,1.14)	0.37 (0.09,1.54)	0.46 (0.16,1.30)	1.16 (0.23,5.84)	Ila10	0.70 (0.26,1.89)
1.18 (0.31,4.49)	1.22 (0.67,2.22)	0.47 (0.21,1.03)	0.42 (0.14,1.30)	0.05 (0.03,0.08)	0.79 (0.56,1.12)	0.61 (0.26,1.43)	<b>0.58</b> <b>(0.42,0.79)</b>	0.53 (0.19,1.47)	<b>0.65</b> <b>(0.46,0.92)</b>	1.66 (0.47,5.91)	1.42 (0.53,3.84)	Eso40

**Table S6 Odds ratios of relative 8-week healing rate for each treatment in the sensitivity analysis**

Vpz40	1.03 (0.28,3.74)	1.55 (0.23,10.58)	1.26 (0.19,8.11)	0.40 (0.09,1.79)	0.36 (0.06,1.97)	0.04 (0.01,0.16)	0.67 (0.17,2.56)	0.51 (0.11,2.39)	0.49 (0.13,1.84)	0.45 (0.09,2.24)	0.55 (0.15,1.98)	1.40 (0.24,8.21)	0.99 (0.23,4.24)	0.82 (0.04,18.79)	0.85 (0.22,3.19)
0.97 (0.27,3.51)	Vpz20	1.51 (0.33,6.79)	1.22 (0.29,5.12)	0.38 (0.15,0.98)	0.35 (0.10,1.18)	0.04 (0.02,0.08)	0.65 (0.35,1.21)	0.50 (0.19,1.32)	0.47 (0.26,0.85)	0.43 (0.14,1.29)	0.53 (0.33,0.86)	1.36 (0.37,5.03)	0.96 (0.42,2.21)	0.79 (0.04,14.41)	0.82 (0.45,1.48)
0.64 (0.09,4.38)	0.66 (0.15,2.99)	Teg50	0.81 (0.19,3.49)	0.25 (0.05,1.25)	0.23 (0.04,1.36)	0.03 (0.01,0.12)	0.43 (0.10,1.79)	0.33 (0.07,1.67)	0.31 (0.08,1.30)	0.29 (0.05,1.60)	0.35 (0.08,1.47)	0.90 (0.14,5.88)	0.64 (0.14,2.88)	0.53 (0.02,12.39)	0.55 (0.14,2.18)
0.80 (0.12,5.13)	0.82 (0.20,3.45)	1.24 (0.29,5.34)	Teg100	0.31 (0.07,1.45)	0.28 (0.05,1.59)	0.03 (0.01,0.13)	0.53 (0.14,2.06)	0.41 (0.09,1.94)	0.39 (0.10,1.49)	0.35 (0.07,1.86)	0.44 (0.11,1.69)	1.12 (0.18,6.88)	0.79 (0.19,3.32)	0.65 (0.03,14.84)	0.67 (0.18,2.50)
2.53 (0.56,11.44)	<b>2.61</b> <b>(1.03,6.63)</b>	3.93 (0.80,19.29)	3.18 (0.69,14.62)	Rab20	0.90 (0.32,2.55)	0.10 (0.04,0.25)	1.69 (0.75,3.82)	1.30 (0.44,3.82)	1.23 (0.60,2.54)	1.13 (0.33,3.88)	1.39 (0.62,3.08)	3.54 (0.83,15.17)	2.51 (0.95,6.68)	2.06 (0.11,39.33)	2.14 (0.98,4.69)
2.80 (0.51,15.45)	2.89 (0.85,9.87)	4.36 (0.73,25.82)	3.52 (0.63,19.71)	1.11 (0.39,3.14)	Rab10	0.12 (0.04,0.37)	1.87 (0.60,5.86)	1.44 (0.38,5.50)	1.37 (0.47,4.01)	1.25 (0.29,5.44)	1.54 (0.50,4.75)	3.93 (0.75,20.63)	2.79 (0.79,9.84)	2.29 (0.11,48.47)	2.37 (0.78,7.26)
24.08 (6.18,93.79)	24.86 (12.81,48.23)	37.43 (8.63,162.37)	30.27 (7.49,122.35)	9.53 (4.07,22.35)	8.59 (2.68,27.59)	Placebo	16.09 (9.85,26.29)	12.35 (5.28,28.84)	11.75 (7.48,18.44)	10.73 (4.12,27.91)	13.21 (8.40,20.78)	33.78 (9.24,123.57)	23.95 (11.22,51.15)	19.66 (1.10,351.18)	20.41 (12.56,33.17)
1.50 (0.39,5.72)	1.54 (0.83,2.88)	2.33 (0.56,9.69)	1.88 (0.49,7.28)	0.59 (0.26,1.34)	0.53 (0.17,1.67)	0.06 (0.04,0.10)	Pan40	0.77 (0.32,1.83)	0.73 (0.50,1.07)	0.67 (0.24,1.85)	0.82 (0.55,1.22)	2.10 (0.59,7.53)	1.49 (0.76,2.93)	1.22 (0.07,21.38)	1.27 (0.90,1.79)
1.95 (0.42,9.09)	2.01 (0.76,5.36)	3.03 (0.60,15.38)	2.45 (0.51,11.67)	0.77 (0.26,2.27)	0.70 (0.18,2.66)	0.08 (0.03,0.19)	1.30 (0.55,3.11)	Ome40	0.95 (0.43,2.12)	0.87 (0.25,3.03)	1.07 (0.46,2.51)	2.74 (0.62,12.06)	1.94 (0.69,5.43)	1.59 (0.08,30.90)	1.65 (0.71,3.86)
2.05 (0.54,7.72)	<b>2.12</b> <b>(1.17,3.82)</b>	3.19 (0.77,13.16)	2.58 (0.67,9.89)	0.81 (0.39,1.67)	0.73 (0.25,2.15)	0.09 (0.05,0.13)	1.37 (0.94,2.00)	1.05 (0.47,2.35)	Ome20	0.91 (0.33,2.49)	1.12 (0.80,1.58)	2.88 (0.81,10.15)	2.04 (1.06,3.94)	1.67 (0.10,29.16)	1.74 (1.28,2.36)
2.24 (0.45,11.30)	2.32 (0.77,6.93)	3.49 (0.63,19.43)	2.82 (0.54,14.80)	0.89 (0.26,3.06)	0.80 (0.18,3.49)	0.09 (0.04,0.24)	1.50 (0.54,4.17)	1.15 (0.33,4.01)	1.10 (0.40,2.99)	Lan60	1.23 (0.46,3.29)	3.15 (0.66,15.04)	2.23 (0.69,7.20)	1.83 (0.09,37.47)	1.90 (0.69,5.25)
1.82 (0.51,6.57)	<b>1.88</b> <b>(1.16,3.05)</b>	2.83 (0.68,11.79)	2.29 (0.59,8.87)	0.72 (0.32,1.60)	0.65 (0.21,2.01)	0.08 (0.05,0.12)	1.22 (0.82,1.80)	0.93 (0.40,2.19)	0.89 (0.63,1.25)	0.81 (0.30,2.17)	Lan30	2.56 (0.76,8.62)	1.81 (0.92,3.57)	1.49 (0.09,26.03)	1.54 (1.10,2.17)

0.71 (0.12,4.17)	0.74 (0.20,2.72)	1.11 (0.17,7.22)	0.90 (0.15,5.52)	0.28 (0.07,1.21)	0.25 (0.05,1.33)	0.03 (0.01,0.11)	0.48 (0.13,1.71)	0.37 (0.08,1.61)	0.35 (0.10,1.23)	0.32 (0.07,1.52)	0.39 (0.12,1.32)	Kev20	0.71 (0.18,2.85)	0.58 (0.03,13.04)	0.60 (0.17,2.13)
1.01 (0.24,4.28)	1.04 (0.45,2.38)	1.56 (0.35,7.03)	1.26 (0.30,5.30)	0.40 (0.15,1.06)	0.36 (0.10,1.27)	0.04 (0.02,0.09)	0.67 (0.34,1.32)	0.52 (0.18,1.44)	<b>0.49</b> <b>(0.25,0.95)</b>	0.45 (0.14,1.44)	0.55 (0.28,1.09)	1.41 (0.35,5.67)	Ila10	0.82 (0.05,14.93)	0.85 (0.47,1.53)
1.22 (0.05,28.17)	1.26 (0.07,23.02)	1.90 (0.08,44.90)	1.54 (0.07,35.16)	0.48 (0.03,9.24)	0.44 (0.02,9.26)	0.05 (0.00,0.91)	0.82 (0.05,14.32)	0.63 (0.03,12.18)	0.60 (0.03,10.40)	0.55 (0.03,11.15)	0.67 (0.04,11.75)	1.72 (0.08,38.48)	1.22 (0.07,22.16)	Fex40	1.04 (0.06,17.78)
1.18 (0.31,4.45)	1.22 (0.67,2.20)	1.83 (0.46,7.33)	1.48 (0.40,5.50)	0.47 (0.21,1.02)	0.42 (0.14,1.29)	0.05 (0.03,0.08)	0.79 (0.56,1.11)	0.60 (0.26,1.41)	<b>0.58</b> <b>(0.42,0.78)</b>	0.53 (0.19,1.45)	<b>0.65</b> <b>(0.46,0.91)</b>	1.66 (0.47,5.85)	1.17 (0.65,2.11)	0.96 (0.06,16.51)	Eso40

**Table S7 Odds ratios of relative 8-week healing rate for each treatment in the subgroup analysis on patients without severe baseline grade**

Vpz40	0.49 (0.10,2.43)	0.73 (0.03,17.50)	0.03 (0.01,0.18)	0.18 (0.03,1.07)	0.36 (0.06,2.02)	0.56 (0.11,2.94)	4.19 (0.14,126.73)	0.30 (0.05,1.74)
2.05 (0.41,10.22)	Vpz20	1.50 (0.09,25.71)	0.06 (0.02,0.18)	0.36 (0.12,1.10)	0.74 (0.28,1.96)	1.15 (0.49,2.71)	8.60 (0.39,190.86)	0.61 (0.21,1.75)
1.37 (0.06,32.90)	0.67 (0.04,11.47)	Rab20	0.04 (0.00,0.64)	0.24 (0.02,3.69)	0.50 (0.03,7.19)	0.77 (0.05,11.51)	5.74 (0.10,321.96)	0.41 (0.03,6.08)
32.52 (5.63,187.75)	15.84 (5.66,44.31)	23.72 (1.56,360.89)	Placebo	5.72 (2.68,12.20)	11.79 (7.00,19.85)	18.18 (10.34,31.95)	136.24 (6.58,2822.24)	9.66 (4.97,18.78)
5.68 (0.93,34.59)	2.77 (0.91,8.45)	4.15 (0.27,63.45)	0.17 (0.08,0.37)	Pan40	2.06 (1.19,3.57)	3.18 (1.56,6.47)	23.82 (1.11,508.71)	1.69 (1.14,2.50)
2.76 (0.49,15.41)	1.34 (0.51,3.55)	2.01 (0.14,29.11)	0.08 (0.05,0.14)	<b>0.49</b> <b>(0.28,0.84)</b>	Ome20	1.54 (0.98,2.42)	11.56 (0.57,234.90)	0.82 (0.54,1.24)
1.79 (0.34,9.41)	0.87 (0.37,2.06)	1.30 (0.09,19.61)	0.06 (0.03,0.10)	<b>0.31</b> <b>(0.15,0.64)</b>	0.65 (0.41,1.02)	Lan30	7.50 (0.38,147.27)	0.53 (0.29,0.98)
0.24 (0.01,7.22)	0.12 (0.01,2.58)	0.17 (0.00,9.76)	0.01 (0.00,0.15)	<b>0.04</b> <b>(0.00,0.90)</b>	0.09 (0.00,1.76)	0.13 (0.01,2.62)	Kev20	0.07 (0.00,1.48)
3.37 (0.57,19.75)	1.64 (0.57,4.71)	2.46 (0.16,36.68)	0.10 (0.05,0.20)	<b>0.59</b> <b>(0.40,0.88)</b>	1.22 (0.81,1.85)	<b>1.88</b> <b>(1.02,3.47)</b>	14.11 (0.67,294.92)	Eso40

**Table S8 Odds ratios of relative 8-week healing rate for each treatment in the subgroup analysis on patients with severe baseline grade**

Vpz40	1.55 (0.23,10.36)	0.76 (0.08,7.66)	0.02 (0.00,0.14)	0.88 (0.13,6.07)	0.76 (0.13,4.60)	0.53 (0.06,4.44)	0.78 (0.14,4.31)	4.36 (0.25,76.32)	1.35 (0.22,8.14)
0.65 (0.10,4.31)	Vpz20	0.49 (0.08,3.00)	0.01 (0.00,0.05)	0.57 (0.17,1.88)	0.49 (0.17,1.45)	0.34 (0.07,1.68)	0.51 (0.19,1.33)	2.81 (0.23,34.10)	0.87 (0.31,2.47)
1.31 (0.13,13.24)	2.04 (0.33,12.44)	Rab20	0.03 (0.01,0.15)	1.16 (0.21,6.32)	1.00 (0.24,4.26)	0.70 (0.10,5.00)	1.03 (0.22,4.90)	5.73 (0.36,92.23)	1.77 (0.37,8.47)
44.80 (7.01,286.15)	69.43 (20.79,231.83)	34.07 (6.47,179.37)	Placebo	39.52 (14.07,110.99)	34.10 (15.11,76.92)	23.80 (7.57,74.81)	35.16 (16.93,73.05)	195.34 (17.49,2182.21)	60.34 (25.98,140.16)
1.13 (0.16,7.80)	1.76 (0.53,5.80)	0.86 (0.16,4.70)	0.03 (0.01,0.07)	Pan40	0.86 (0.36,2.09)	0.60 (0.14,2.66)	0.89 (0.36,2.19)	4.94 (0.42,58.41)	1.53 (0.80,2.91)
1.31 (0.22,7.94)	2.04 (0.69,6.02)	1.00 (0.23,4.25)	0.03 (0.01,0.07)	1.16 (0.48,2.80)	Ome20	0.70 (0.18,2.65)	1.03 (0.58,1.83)	5.73 (0.54,61.34)	1.77 (0.98,3.21)
1.88 (0.23,15.72)	2.92 (0.59,14.31)	1.43 (0.20,10.25)	0.04 (0.01,0.13)	1.66 (0.38,7.32)	1.43 (0.38,5.43)	Lan60	1.48 (0.42,5.24)	8.21 (0.59,113.33)	2.54 (0.66,9.75)
1.27 (0.23,7.00)	1.97 (0.75,5.19)	0.97 (0.20,4.60)	0.03 (0.01,0.06)	1.12 (0.46,2.76)	0.97 (0.55,1.72)	0.68 (0.19,2.40)	Lan30	5.56 (0.56,55.41)	1.72 (0.97,3.04)
0.23 (0.01,4.01)	0.36 (0.03,4.31)	0.17 (0.01,2.81)	0.01 (0.00,0.06)	0.20 (0.02,2.39)	0.17 (0.02,1.87)	0.12 (0.01,1.68)	0.18 (0.02,1.80)	Kev20	0.31 (0.03,3.30)
0.74 (0.12,4.49)	1.15 (0.40,3.27)	0.56 (0.12,2.70)	0.02 (0.01,0.04)	0.65 (0.34,1.25)	0.57 (0.31,1.02)	0.39 (0.10,1.52)	0.58 (0.33,1.03)	3.24 (0.30,34.63)	Eso40

**Table S9 Odds ratios of pooled 4-week vs 8-week healing rate by each treatment**

	Pooled healing rate (% , 95%CI)		OR	95%CI	<i>P</i>
	4-week	8-week			
Teg50	88%(80%~94%)	96%(90%~99%)	0.303	0.094~0.978	<0.001
Kev20	82%(74%~89%)	96%(90%~99%)	0.205	0.074~0.563	<0.001
Teg100	90%(83%~95%)	95%(89%~98%)	0.474	0.156~1.440	0.188
Vpz20	93%(85%~98%)	96%(92%~98%)	0.473	0.286~0.782	0.003
Ila10	77%(73%~81%)	86%(80%~90%)	0.61	0.431~0.865	<0.001
Vpz40	97%(93%~99%)	97%(93%~99%)	1	0.245~4.084	1
Eso40	76%(72%~80%)	91%(88%~93%)	0.322	0.262~0.396	<0.001
Fex40	90%(83%~95%)	99%(95%~100%)	0.088	0.011~0.698	<0.001
Pan40	73%(69%~77%)	92%(89%~95%)	0.301	0.243~0.373	<0.001
Lan30	77%(69%~94%)	88%(84%~91%)	0.438	0.360~0.533	<0.001
Ome40	44%(34%~55%)	73%(62%~91%)	0.298	0.160~0.553	<0.001
Lan60	76%(65%~85%)	89%(79%~95%)	0.406	0.171~0.964	<0.001
Ome20	73%(64%~80%)	88%(84%~91%)	0.355	0.290~0.436	<0.001
Rab20	88%(85%~91%)	94%(89%~98%)	0.399	0.207~0.767	<0.001
Rab10	85%(77%~92%)	91%(84%~96%)	0.562	0.234~1.349	0.197